Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoform

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Novel phosphoinositide 3-kinase (PI3K) inhibitors are crucial for overcoming resistance and poor tolerability in clinical settings.
• Brusatol, a quassinoid, exhibits specific inhibitory activity against hematologic malignancies, but its anti-cancer mechanism remains unclear.

Purpose of the Study:

• To investigate the anti-cancer activity and mechanism of Brusatol in hematologic malignancies.
• To develop and evaluate novel synthetic analogs of Brusatol as potential PI3K inhibitors.

Main Methods:

• Screening Brusatol activity across various hematologic malignancy cell lines.
• Identifying direct molecular targets of Brusatol using cellular assays.
• Synthesizing and testing novel Brusatol analogs in vitro and in vivo.
• Evaluating toxicity in normal human cells and mouse models.

Main Results:

• The PI3Kγ isoform was identified as a direct target of Brusatol.
• Brusatol's inhibitory effect was significantly reduced in cells with lower PI3Kγ expression.
• Novel synthetic analogs demonstrated comparable or superior potency against malignant hematologic cell lines.
• One analog exhibited minimal toxicity to normal cells and in vivo models.

Conclusions:

• Brusatol's anti-cancer activity in hematologic malignancies is mediated through direct inhibition of the PI3Kγ isoform.
• Developed Brusatol analogs represent a promising new class of PI3K inhibitors.
• These analogs possess enhanced potential for therapeutic development in hematologic malignancies with improved safety profiles.